LEXICON PHARMACEUTICALS, INC. (LXRX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 51.44M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 190.61M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 250.06M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | $51.44M | (m) | $190.61M | $250.06M | (m) |
| 2026-03-31 | (m) | (m) | $0.00 | $49.68M | (m) | $170.66M | $268.82M | (m) |
| 2025-12-31 | (m) | (m) | $4.59M | $49.41M | (m) | $96.23M | $184.99M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $56.51M | (m) | $115.95M | $205.93M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $56.11M | (m) | $139.01M | $225.58M | (m) |
| 2025-03-31 | (m) | (m) | $42.06M | $58.64M | (m) | $194.84M | $297.67M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $100.30M | (m) | $237.96M | $298.42M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $99.89M | (m) | $258.37M | $321.12M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $99.50M | (m) | $309.96M | $373.36M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $99.87M | (m) | $355.60M | $417.22M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $99.51M | (m) | $170.03M | $229.43M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $99.27M | (m) | $218.43M | $276.48M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $98.77M | (m) | $256.74M | $316.72M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $48.84M | (m) | $105.94M | $162.72M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $48.58M | (m) | $64.68M | $194.30M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $23.78M | (m) | $136.20M | $191.69M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $23.63M | (m) | $61.97M | $112.33M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $23.48M | (m) | (m) | $136.18M | (m) |
| 2021-12-31 | (m) | (m) | $0.00 | (m) | (m) | $79.18M | $136.91M | (m) |
| 2021-09-30 | (m) | (m) | $11.69M | (m) | (m) | (m) | $172.33M | (m) |
| 2021-06-30 | (m) | (m) | $11.68M | (m) | (m) | (m) | $171.67M | (m) |
| 2021-03-31 | (m) | (m) | $11.66M | (m) | (m) | (m) | $193.26M | (m) |
| 2020-12-31 | (m) | (m) | $11.65M | $0.00 | (m) | $152.28M | $203.79M | (m) |
| 2020-09-30 | (m) | (m) | $8.69M | $11.63M | (m) | (m) | $178.93M | (m) |
| 2020-06-30 | (m) | (m) | $10.46M | $234.81M | (m) | (m) | $322.54M | (m) |
| 2020-03-31 | (m) | (m) | $10.73M | $234.49M | (m) | (m) | $370.57M | (m) |
| 2019-12-31 | (m) | (m) | $11.01M | $234.17M | (m) | (m) | $417.71M | (m) |
| 2019-09-30 | (m) | (m) | $11.29M | $233.84M | (m) | (m) | $444.59M | (m) |
| 2019-06-30 | (m) | (m) | $1.11M | $243.95M | (m) | (m) | $233.14M | (m) |
| 2019-03-31 | (m) | (m) | $1.11M | $243.91M | (m) | (m) | $258.52M | (m) |
| 2018-12-31 | (m) | (m) | $1.11M | $243.89M | (m) | (m) | $284.14M | (m) |
| 2018-09-30 | (m) | (m) | $1.11M | $243.83M | (m) | (m) | $310.19M | (m) |
| 2018-06-30 | (m) | (m) | $12.90M | $232.20M | (m) | (m) | $332.94M | (m) |
| 2018-03-31 | (m) | (m) | $13.52M | $231.88M | (m) | (m) | $386.81M | (m) |
| 2017-12-31 | (m) | (m) | $14.09M | $231.58M | (m) | (m) | $436.54M | (m) |
| 2017-09-30 | (m) | (m) | $14.63M | $85.51M | (m) | (m) | $329.49M | (m) |
| 2017-06-30 | (m) | (m) | $15.16M | $85.38M | (m) | (m) | $363.51M | (m) |
| 2017-03-31 | (m) | (m) | $15.75M | $85.27M | (m) | (m) | $396.26M | (m) |
| 2016-12-31 | (m) | (m) | $16.28M | $85.17M | (m) | (m) | $475.63M | (m) |
| 2016-09-30 | (m) | (m) | $16.79M | $85.04M | (m) | (m) | $516.95M | (m) |
| 2016-06-30 | (m) | (m) | $17.29M | $84.91M | (m) | (m) | $558.13M | (m) |
| 2016-03-31 | (m) | (m) | $2.02M | $100.55M | (m) | (m) | $611.34M | (m) |
| 2015-12-31 | (m) | (m) | $2.02M | $103.79M | (m) | (m) | $654.83M | (m) |
| 2015-09-30 | (m) | (m) | $18.79M | $87.50M | (m) | (m) | $391.14M | (m) |
| 2015-06-30 | (m) | (m) | $19.25M | $87.50M | (m) | (m) | $415.96M | (m) |
| 2015-03-31 | (m) | (m) | $19.71M | $87.50M | (m) | (m) | $444.68M | (m) |
| 2014-12-31 | (m) | (m) | $20.17M | $87.50M | (m) | (m) | $471.38M | (m) |
| 2014-09-30 | (m) | (m) | $20.61M | $0.00 | (m) | (m) | $187.52M | (m) |
| 2014-06-30 | (m) | (m) | $1.78M | $19.25M | (m) | (m) | $224.06M | (m) |
| 2014-03-31 | (m) | (m) | $1.75M | $19.71M | (m) | (m) | $243.60M | (m) |
| 2013-12-31 | (m) | (m) | $1.71M | $20.17M | (m) | (m) | $274.16M | (m) |
| 2013-09-30 | (m) | (m) | $1.68M | $20.61M | (m) | (m) | $299.46M | (m) |
| 2013-06-30 | (m) | (m) | $22.68M | $0.00 | (m) | (m) | $323.39M | (m) |
| 2013-03-31 | (m) | (m) | $1.61M | $21.46M | (m) | (m) | $347.27M | (m) |
| 2012-12-31 | (m) | (m) | $1.57M | $21.88M | (m) | (m) | $371.78M | (m) |
| 2012-09-30 | (m) | (m) | $1.54M | $22.28M | (m) | (m) | $357.83M | (m) |
| 2012-06-30 | (m) | (m) | $1.51M | $22.68M | (m) | (m) | $381.06M | (m) |
| 2012-03-31 | (m) | (m) | $1.48M | $23.06M | (m) | (m) | $402.79M | (m) |
| 2011-12-31 | (m) | (m) | $1.44M | $23.45M | (m) | (m) | $430.51M | (m) |
| 2011-09-30 | (m) | (m) | $1.41M | $23.83M | (m) | (m) | $294.71M | (m) |
| 2011-06-30 | (m) | (m) | $1.38M | $24.19M | (m) | (m) | $315.92M | (m) |
| 2010-12-31 | (m) | (m) | $1.14M | $27.34M | (m) | (m) | $366.88M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |